Bayer's Stivarga accepted for use by NHS Scotland

13 April 2015

The Scottish Medicines Consortium (SMC) today announced that German pharma major Bayer’s (BAYN: DE) Stivarga (regorafenib) has been accepted for use within NHS Scotland for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.

GIST is the most common form of sarcoma arising from the muscle wall of the gastrointestinal tract.GIST represents a life-threatening malignancy if the disease has spread to other parts of the body (metastasized) or is unable to be surgically removed with curative intent.GIST affects an estimated 10-20 patients per million per year worldwide.

Stivarga generated sales of 224 million euros ($238 million) in 2014, and is one of the five recently-launched drugs for which Bayer is forecasting blockbuster sales. Regorafenib has demonstrated a statistically-significant improvement in progression-free survival compared to placebo in patients with GIST whose disease had progressed after prior treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK